GFI #256: Compounding in companion animal medicine

The U.S. Food and Drug Administration’s Guidance for Industry (GFI) #256, Compounding Animal Drugs from Bulk Drug Substances describes how products compounded from bulk drug substances are used in veterinary medicine. In this presentation, companion animal practitioners learn how GFI #256 applies to your day-to-day work, including compounding drugs in the clinic, ordering compounded medications for an individual patient, and keeping compounded drugs on the shelf as office stock. Come away with a practical understanding of the guidance as it pertains to you and your team. Note: This webinar is limited to compounding for companion animals and does not cover food-producing animals.     

Learning objectives: 

• Learn about the scope of GFI #256, including what it does and does not address. 
• Understand that the lists do not apply to ordering or calling in a script for a specific patient but only apply to what is ordered to keep as office stock for immediate use.
• Discover why it’s important to submit nominations to the AVMA for drugs to be included on FDA's list of bulk drug substances.

As an assistant director in AVMA’s Division of Animal and Public Health, Dr. Dharati Szymanski serves as staff consultant to the Council on Biologic and Therapeutic Agents, the Clinical Practitioners’ Advisory Committee, the Council on Public Health, and the Food Safety Advisory Committee. Before joining the AVMA, she served as a shelter veterinarian in the Chicago area and a companion animal veterinarian in the Chicago and Washington, D.C areas.